Seebri Breezhaler 50 microgram, inhalation powder hard capsules

USDailyMed:Glycopyrrolate AU:B2 A03AB02(WHO)D11AA01(WHO)R03BB06(WHO) AU:S3 / S4CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 3-[2-Cyclopentyl(hydroxy)phenylacetoxy]-1,1-dimethylpyrrolidinium bromide 51186-83-5Yas cation:596-51-0 3494as cation:11693 7459 DBSALT001183Yas cation:DB00986 11201as cation:3374 V92SO9WP2Ias cation:A14FB57V1D D00540Yas cation:D10938 CHEBI:90972 ChEMBL1201027Nas cation:ChEMBL1201335 DTXSID6023109 Interactive imageas cation:Interactive image C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C.[Br-]as cation: C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C InChI=1S/C19H28NO3.BrH/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;1H/q+1;/p-1Key:VPNYRYCIDCJBOM-UHFFFAOYSA-Mas cation: InChI=1S/C19H28NO3/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3/q+1Key:ANGKOCUUWGHLCE-UHFFFAOYSA-N Glycopyrronium bromideis amedicationof themuscarinicanticholinergicgroup.It does not cross theblood–brain barrierand consequently has few to no central effects. It can be administeredorally,intravenously,topically,or viainhalation.It is a syntheticquaternary ammonium compound.Thecation, which is the activemoiety, is calledglycopyrronium(INN)orglycopyrrolate(USAN). The most common side effects includeirritability,flushing,nasal congestion, reduced secretions in the airways,dry mouth,constipation,diarrhea,nauseaandvomiting, andurinary retention. In September 2012, glycopyrronium was approved for medical use in the European Union.In June 2018, glycopyrronium was approved by the U.S.Food and Drug Administration(FDA) to treat excessive underarm sweating, becoming the first drug developed specifically to reduce excessive sweating.It is on theWorld Health Organization's List of Essential Medicines.